In vitro activities of antibiotic combinations against clinical isolates of Pseudomonas aeruginosa

Kaohsiung Journal of Medical Sciences

Volumn 20, Issue 6, 2004, Pages 261-267

  Chen, Yen Hsu ^a   Peng, Chien Fang ^b   Lu, Po Liang ^a,b   Tsai, Jih Jin ^a   Chen, Tyen Po ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Antimicrobial combination; In vitro susceptibility; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFEPIME; CIPROFLOXACIN; PIPERACILLIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG CHOICE; DRUG INDICATION; DRUG POTENTIATION; IN VITRO STUDY; MEDICAL DECISION MAKING; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREVALENCE; PSEUDOMONAS AERUGINOSA; TAIWAN; TREATMENT PLANNING;

EID: 3142730591     PISSN: 02575655     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1607-551x(09)70116-0     Document Type: Article

References (32)

1. NNIS System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued in August 2003. Am J Infect Control 2003;31:481-98.
2. Lin CJ, Lu PL, Hwang PL, et al. Secular trends of nosocomial infections in a medical center from 1985 to 1996. Nosocomial Infect Control J 2000;10:301-12.
3. Francioli P, Chastre J, Langer M, et al. Ventilator-associated pneumonia - understanding epidemiology and pathogenesis to guide prevention and empiric therapy. Clin Microbiol Infect 1997;3(Suppl 1):S61-76.
4. Spencer RC. Predominant pathogens found in the European Prevalence of Infection in Intensive Care Study. Eur J Clin Microbiol Infect Dis 1996;15:281-5.
5. Carmeli Y, Troillet N, Karchmer AW, et al. Health and economic outcome of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 1999;159:1127-32.
6. Troillet N, Samore MH, Carmeli Y. Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin Infect Dis 1997;25:1094-8.
7. Hilf M, Yu VL, Sharp J, et al. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989;87:540-6.
8. Arnoff SC, Klinger JD. In vitro activities of aztreonam, piperacillin, and ticarcillin combined with amikacin against amikacin-resistant Pseudomonas aeruginosa and Pseudomonas cepacia from children with cystic fibrosis. Antimicrob Agents Chemother 1984;25:279-80.
9. Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother 1997;40:639-51.
10. Performance Standards for Antimicrobial Susceptibility Testing, eighth informational supplement. Approved standard, document M100-S8. Wayne, PA: National Committee for Clinical Laboratory Standards, 1998.
11. Performance Standards for Antimicrobial Disk Susceptibility Tests, approved standard, document M2-A6. Villanova, PA: National Committee for Clinical Laboratory Standards, 1997.
12. th edition. Baltimore: Williams and Wilkins, 1996:330-96.
13. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003;52:1.
14. Hsueh PR, Liu CY, Luh KT. Current status of antimicrobial resistance in Taiwan. Emerg Infect Dis 2002;8:132-7.
15. Gales AC, Jones RN, Turnidge J, et al. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001;32(Suppl 2):S146-155.
16. Hanberger H, Garcia-Rodriguez JA, Gobernado M, et al. Antibiotic susceptibility among aerobic Gram-negative bacilli in intensive care units in 5 European countries. JAMA 1999;281: 1-5.
17. Jones RN, Kirby JT, Beach ML, et al. Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY antimicrobial surveillance program (1997-2000). Diagn Microbiol Infect Dis 2002;43:239-43.
18. Bosso JA, Saxon BA, Matsen JM. In vitro activities of combinations of aztreonam, ciprofloxacin, and ceftazidime against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis. Antimicrob Agents Chemother 1990;34:487-8.
19. Meyer RD, Liu S. In vitro synergy studies with ciprofloxacin and selected beta-lactam agents and aminoglycosides against multidrug-resistant Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 1988;11:151-7.
20. Kuck NA, Testa RT, Forbes M. In vitro and in vivo antibacterial effects of combinations of beta-lactam antibiotics. Antimicrob Agents Chemother 1981;19:634-8.
21. Lister PD, Sanders WE Jr, Sanders CC. Cefepime-aztreonam: a unique double beta-lactam combination for Pseudomonas aeruginosa. Antimicrob Agents Chemother 1998;42:1610-9.
22. Sader HS, Huynh HK, Jones RN. Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and beta-lactams tested against Gram-negative bacilli. Diagn Microbiol Infect Dis 2003;47:547-50.
23. Bosso JA, Saxon BA, Maxtsen JM. Comparative activity of cefepime, alone and in combination, against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients. Antimicrob Agents Chemother 1991;35:783-4.
24. McGrath BJ, Bailey EM, Lamp KC, et al. Pharmacodynamics of once-daily amikacin in various combinations with cefepime, aztreonam, and ceftazidime against Pseudomonas aeruginosa in an in vitro infection model. Antimicrob Agents Chemother 1992; 36:2741-6.
25. Fish DN, Choi MK, Jung R. Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs. J Antimicrob Chemother 2002; 50:1045-9.
26. Pohlman JK, Knapp CC, Ludwig MD, et al. Timed killing kinetic studies of the interaction between ciprofloxacin and beta-lactams against Gram-negative bacilli. Diagn Microbiol Infect Dis 1996;26:29-33.
27. Gradelski E, Valera L, Bonner D, Fung-Tomc J. Synergistic activities of gatifloxacin in combination with other antimicrobial agents against Pseudomonas aeruginosa and related species. Antimicrob Agents Chemother 2001;45:3220-2.
28. Isenberg HD, Alperstein P, France K. In vitro activity of ciprofloxacin, levofloxacin, and trovafloxacin, alone and in combination with beta-lactams, against clinical isolates of Pseudomonas aeruginosa, Stenotrophomonas maltophila, and Burkholderia cepacia. Diagn Microbiol Infect Dis 1999;33:81-6.
29. Song W, Woo HJ, Kim JS, et al. In vitro activity of beta-lactams in combination with other antimicrobial agents against resistant strains of Pseudomonas aeruginosa. Int J Antimicrob Agents 2003;21:8-12.
30. Cappelletty DM, Rybak MJ. Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996;40:677-83.
31. Visalli MA, Jacobs MR, Appelbaum PC. Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology. Antimicrob Agents Chemother 1998;42: 953-5.
32. Burgess DS, Hastings RW. Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill. Diagn Microbiol Infect Dis 2000;38:3741.